Drugs / IMX-110
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05840835 | Feb 2023 → Jan 2024 | neoplasm | Immix Biopharma, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT03382340 | Feb 2018 → Oct 2023 | breast cancer, malignant pancreatic neoplasm, ovarian cancer | Immix Biopharma, Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMX-110 | “IMX-110 in Patients With Advanced Solid Tumors” NCT03382340 ↗ |
| Action | Inhibit | “Stat3/NF-kB/poly-tyrosine kinase inhibitor” NCT03382340 ↗ |
| Modality | Other / unclassified | “a nanoparticle encapsulating a Stat3/NF-kB/poly-tyrosine kinase inhibitor and low-dose doxorubicin” NCT03382340 ↗ |
| Target | STAT3 | “Stat3/NF-kB/poly-tyrosine kinase inhibitor” NCT03382340 ↗ |